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The aim of this review is to compare the
experimental evidence obtained from in vitro
studies on the effect of amphetamine and
methyiphenidate on dopamine transmission with
the results obtained in animal models of
attention deficit hyperactivity disorder (ADHD).
This comparison can extend the knowledge on
the mechanism of action of the drugs used in
the therapy of ADHD and provide insight into
the etiology of ADHD. In particular, we
considered the results obtained from in vitro
methods, such as synaptosomes, cells in culture,
and slices and from in vivo animal models of
ADHD, such as spontaneous hypertensive rats
(SHR) and the Naples high-excitability (NHE)
rat lines. The different experimental approaches
produce consonant results and suggest that in
SHR rats, in contrast to Wistar Kyoto rats
(WKY), amphetamine and depolarization by
high K
/ might release different pools of
dopamine-containing vesicles. The pool depleted
by amphetamine might represent dopamine
that is stored in large dense core vesicles,
whereas dopamine released by high K
/ might
be contained in small synaptic vesicles (SSV).
The sustained dopamine transmission observed
in the nucleus accumbens of SHR but not WKY
rats can be supported by an elevated synthesis
and release, which also might explain the
stronger effect of methylphenidate on dopamine
release in SHR but not in WKY rats. This
hypothesis might enlighten the common
therapeutic effect of these drugs, although their
action takes place at different levels in
catecholaminergic transmission.
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INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD)
is a clinically heterogeneous disorder with an onset
in infancy characterized by the presence of three
principal symptoms" hyperactivity, inattention, and
impulsivity (Oades, 1998). Results from neuro-
psychological and neuroimaging studies suggest
that abnormalities of the prefrontal cortex coexist
with a dysfunction of subcortical areas that project
to the prefrontal cortex, leading to the definition of
’frontosubcortical alteration’, an expression that
reflects the complexity of this disorder and answers
questions on the site of the defect that causes
ADHD (see Faraone & Biederman, 2002, for
review). The treatment ofADHD is represented by
drugs that raise the synaptic concentration of
dopamine and norepinephrine through different
mechanisms. Although the first line oftreatment is
represented by psychostimulants like methylpheni-
date and dextroamphetamine (Whalen et al., 1989;
Solanto, 1998), tricyclic antidepressants can be
used while weighing the risks and benefits because
of their moderate to strong side effects. Anti-
depressants that can be used in ADHD therapy are
drugs like imipramine, desipramine, clomipramine,
nortriptiline, and amytriptiline that block the
reuptake of norepinephrine and serotonin (Wilens
et al., 1995; Spencer et al., 2002; Pliszka, 2003),
but not the selective serotonin reuptake inhibitor
(SSRI) (Biederman et al., 1997).
The increase of catecholamine transmission,
either at the level of the basal ganglia or at the
level of the prefrontal cortex, might be the key to
the medication potential of psychostimulants and
antidepressants. The study of synaptosomes, slices,
vesicles, and cells in culture has contributed to
elucidating the mechanism of act;.on of
amphetamine and its involvement in vesicle
trafficking at the catecholaminergic terminal level.
This issue was recently reviewed by Schmitz et al.
(2003). The aim ofthe present review is to provide
a further contribution to explaining the effect of
amphetamine, methylphenidate, and depolarization
by high K
/ on dopamine release, as estimated by in
vivo microdialysis in animal models ofADHD and
to compare the evidence obtained with that from in
vitro methods. This comparison can lead to the
recognition of the advantages and the limitations
of each method used to study the vesicle trafficking
involved in dopamine release and provide insight
into the etiology ofADHD and the mechanism of
the medication effect ofpsychostimulants.
ANIMAL MODELS OF ADHD
In vivo experimentation on ADHD medications
can be performed in different animal models of
ADHD (Davids et al., 2003). Among them,
spontaneously hypertensive rats (SHR) (Yamory et
al., 1984) have been widely investigated because
relative to their Wistar-Kyoto (WKY) normo-
tensive controls, SHR rats show behavioral
abnormalities (hyperactivity and hyper-reactivity
to stress) (Knardahl & Sagvolden, 1979) that
resemble those of human ADHD. Moreover, when
compared with WKY controls, SHR rats exhibit
increased activity when exposed to different
contexts (Sagvolden et al., 1992a,b), a heightened
response to stress with marked increase of plasma
catecholamines (Chiueh, 1981), altered reinforce-
ment mechanisms (Berger & Sagvolden, 1998),
deficient sustained attention (Sagvolden, 2000),
and impaired acquisition of operant tasks (Wyss,
1992; Mook et al., 1993; Sagvolden, 2000).
Spontaneously hypertensive rats also have a
reduced number of Ca2//calmodulin-dependent
proteinkinase II (CaMKII) elements and a lower
expression of the peptide product of the FOS
family and ZIF-268 in the shell of the nucleus
aceumbens (NAt) (Papa et al., 1998). Moreover,
in SHR rats, CaMKII levels can be normalized by
chronic methylphenidate treatment.
In view of the evaluation of the effects of
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blockers on SHR rats, we must point out that SHR
rats have a greater rate of norepinephrine uptake,
mediated by the norepi-nephrine transporter
(NET), in the frontal cortex during early
development, and that such changes are accounted
for by an increased Vmax of the norepinephrine
uptake mechanism (Myers et al., 1981). Moreover,
the authors detected a significant decrease in
dopamine uptake in the frontal cortex and striatum
of the SHR at 6 weeks of age, thus suggesting an
important role for dopamine in the development of
both hypertension and behavioral hyperactivity
exhibited by these animals. An interesting study on
the expression pattern ofthe specific genes involved
in dopamine neuron differentiation, survival, and
functioning during postnatal development of the
ventral midbrain in SHR males has shown that
tyrosine hydroxylase (TH) and dopamine
transporter (DAT) gene expression are
significantly reduced in the SHR midbrain during
the first month of postnatal development (Leo et
al., 2003).
A promising new animal model of ADHD is
represented by WKHA rats (Hendley & Fan, 1992;
Hendley, 2000). The WKHA rats, selected by
cross-breeding SHR and WKY, are normotensive
but maintain certain behavioral features of SHR,
such as hyperactivity in a novel environment and
hyper-reactivity to stress; WKHA rats are less
aggressive than SHR and habituate more readily to
a novel environment. Neurochemical studies have
suggested that the WKHA strain shows the lowest
rate of norepinephrine uptake in the frontal cortex
and the highest uptake rate of dopamine when
compared with SHR, WKY, and WKHT (a WKY-
derived strain of hypertensive rats that are not
hyperactive).
Another animal model ofADHD is represented
by dopamine transporter knockout mice (DAT-KO)
(Giros et al., 1996) that have an elevated synaptic
dopamine concentration in the striatum and the
nucleus aecumbens (NAt) (Carboni et al., 2001)
and show hyperactivity and learning impairment
(Gainetdinov et al., 1998, 2001). Recently the
Naples high-excitability (NHE) rat line was also
proposed as an animal model of ADHD for its
increased behavioral activity and impaired
attention, which might be due to a
hyperfunctioning of the meso-corticolimbic
dopamine system (Sadile et al., 1993; Papa et al.,
1995; 2002; Gonzales-Lima & Sadile, 2000). In
summary, although several animal strains may be
hyperactive and show attention deficit, the SHR
strain shows the highest number of behavioral
symptoms resembling those observed in ADHD
(Sagvolden, 2000).
TRANSMITTERS, TRASPORTERS AND
BRAIN AREAS INVOLVED IN ADHD
Investigations on dopamine transmission in the
prefrontal cortex (PFCX) and in subcortical areas,
i.e. caudate putamen and NAc, has provided clues
on the specific neuronal mechanism that could be
responsible for the behavioral features of animal
models ofADHD (Linthorst et al., 1991; Sagvolden
& Sergeant, 1998; Robbins et al., 2002; Spencer et
al., 2002, So!anto, 2002). The PFCX and the ventral
tegmental area (VTA) are reciprocally connected
by dopamine afferents and glutamatergic efferents.
Ventral tegmental area dopamine neurons are
involved in working memory and in executive
functions, such as motor planning, inhibitory-
response control, and sustained attention (Fibiger
& Phillips, 1986; Granon et al., 2000; Robbins,
2002). The caudate putamen and the NAc receive
a dense innervation from the substantia nigra and
the VTA, respectively, and play a crucial role in
motor behavior and motivation (Di Chiara et al.,
1992; Almaric & Koob 1993; Woodward et al.,
1999). The NAc, in turn, can be subdivided into
two regions, the shell and the core (Deutch &
Cameron, 1992; Zham & Heimer, 1993). Dopamine
transmission in the shell is involved in emotional
and motivational processes related to reinforcement80 E. CARBONI AND A. SILVAGNI
(Di Chiara, 2002). In particular, dopamine trans-
mission in the NAc might be of particular relevance
in ADHD because impulsiveness and premature
responding may be related to the grade of
efficiency or rewarding/reinforcing mechanism
(Sagvolden & Sergeant, 1998).
Children with ADHD tested in attentional
tasks were shown to prefer an immediate
reinforcement instead of waiting for a delayed one
(Sonuga-Barke et al., 1992). Additionally, in tests
addressed to show changes in rates of responding
throughout fixed-interval schedules of reinforce-
ment of bar-presses for water, SHR behavior was
more sensitive to immediate reinforcement but was
proportionately less sensitive to delayed
reinforcement when compared with the behavior
ofWKY rats (Sagvolden et al., 1992a, b). In similar
tests, the SHR strain can maintain high rates of
responding only if reinforcers are infrequent
(Sagvolden et al., 1993). Moreover, psychomotor
stimulants acted by strengthening the control by
delayed reinforcers, an action consistent with
clinical observations that ADHD children are less
willing than others to accept ’delayed
gratification’ and that methyl-phenidate increases
the control of delayed reward over their behavior
(Sagvolden et al., 1992a, b).
Although DAT-KO mice show hyperactivity
and an elevated dopamine synaptic concentration,
studies on the function of the DAT in ADHD
suggest a higher expression of DAT sites in the
basal ganglia of adults that suffered from ADHD
during childhood (Dougherty et al., 1999) and in
children affected by ADHD (Cheon et al., 2003).
Therefore, the role of the DAT in the behavioral
features ofADHD subjects or in animal models of
ADHD remains to be elucidated. Moreover, a
correlation between the expression ofDAT and the
severity of symptoms was not found in these
studies. A higher expression ofDAT sites was also
found in the caudate-putamen of SHR compared
with WKY rats, both at pre- and post-hypertensive
stages, (Watanabe et al., 1997). Kujirai et al.
(1990), however, did not find any difference
between SHR and WKY in 3H-mazindol-labeled
dopamine uptake sites.
Understanding the consequences of an
alteration of DAT expression in ADHD is further
complicated by the brain area considered. If
indeed, in areas like the caudate putamen and the
NAc, the DAT is the primary mechanism of
clearance of dopamine released, then a different
situation may be encountered in the PFCX, where
the role ofDAT and eventually its alteration is less
clear because the clearance of transmitters is
accomplished mainly by diffusion rather than by
reuptake in dopamine terminals. In the PFCX,
indeed a lower number ofDAT sites are present as
compared with th e NAc and striatum (Garris &
Wightman 1994; Clements 1996; Sesak et al.,
1998).
A contribution to the removal of dopamine
from the extracellular space in the PFCX can also
be provided by norepinephrine terminals (Carboni
et al., 1990, Yamamoto & Novotney, 1988). The
expression of DAT in the NAc of SHR rats is
unknown; how a higher expression of DAT might
explain the higher basal dopamine concentration in
the NAc of SHR rats as compared with WKY rats
(Carboni et al., 2003) is unclear. It is indeed more
likely that a higher synaptic dopamine concentration
is associated with reduced DAT activity. An
increased number ofDAT sites and the consequent
reduced dopamine synaptic concentration hardly
fit with the hyperactivity typical of the ADHD
syndrome. In fact, in DAT-KO mice, hypermotility
and an elevated extracellular dopamine concen-
tration in the caudate putamen and in the NAc
(Carboni et al., 2001) is associated with KO (Giros
et al., 1996) and knock down (KD) (Zhuang et al.,
2001) ofthe DAT gene.
Moreover, as amphetamine reduces hyper-
motility in DAT-KO mice, it has been suggested
that DAT-KO and DAT-KD support the
hyperdopaminergic hypothesis ofADHD (Solanto,
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by the finding that the dopamine agonist
apomorphine, although producing biphasic effects
(hypomotility at low doses and hypermotility at
high doses) in wild mice and in WKY rats, induces
only hypomotility in KD mice and SHR rats at low
and high doses (Fuller et al., 1983; Zhuang et al.,
2001).
MECHANISM OF ACTION OF DRUGS
USED IN ADHD THERAPY
Most studies aiming to clarify the mechanism
of action of amphetamine have been addressed to
vesicle trafficking in the dopamine terminal.
Amphetamine can enter the terminal, either
through the DAT (Liang & Rutledge, 1982) or by
membrane diffusion, due to its lipophilic properties
(Mack & Bonisch, 1979). In the neuron terminal,
amphetamine can label the vesicular monoamine
transporter VMAT2 (Sulzer & Rayport, 1990) and,
dissipating the pH that drives vesicular
monoamine uptake (Sulzer et al., 1995), generates
the dopamine efflux (Heikkila, 1975). Dopamine,
in turn, can diffuse into the terminal cytoplasm and
leave it through the inversion of the transport
direction of the DAT (Sulzer et al., 1995; Jones et
al., 1998). Vesicular monoamine stores, therefore,
can play a significant role in locomotor activity,
attention, and reinforcing processes as confirmed
in heterozygotic VMAT-2 KO mice, in which
amphetamine produces enhanced locomotor activity
but diminished behavior reward (Takahashi et al.,
1997).
A complementary hypothesis tested in
chromaffin cells (Mundorf, 1999) suggests that
amphetamine can disrupt vesicular stores to a
sufficient degree that Ca
++ stored together with
dopamine in the terminal vesicles, can escape and
trigger the exocytosis of vesicles that are close to
the plasmalemmal membrane. A similar mechanism
has been proposed for neuronal systems, such as
the cholinergic terminals, where acetylcholine
release can occur during large inward calcium
currents involving many simultaneously opening
channels but also through very small calcium
transients’ entry through only one channel opening
at a time (Stanley, 1993).
A more intriguing action of amphetamine was
observed in the rat amygdala, where it induces
long-term depression of synaptic transmission by
CB cannabinoid receptors. Amphetamine-induced
endocannabinoid release depends indeed on a rise
in intracellular calcium by an undisclosed,
mechanism (Huang et al., 2003). The possible effect
of amphetamine on cannabinoid transmission in
ADHD subjects or in animal models can be
investigated further in view of the studies by
Ehrenreich et al., (1999), who tested the
hypothesis that chronic interference by cannabis
with endogenous cannabinoid systems during
peripubertal development can cause specific and
persistent alterations of attentional functions. The
authors indeed reported that beginning cannabis
use during early adolescence could lead to
enduring effects on specific attentional functions
in adulthood. Inherent with this evidence, Viggiano
et al. (2003) studied the influence of endocanna-
binoid as a neurotrophic factor on developing
mesencephalic dopamine neurons in NHE rats
using a prenatal elevation of anandamide. The
authors reported that the offspring of rats treated
with AM-404 showed a reduction in behavioral
activity and attention tests.
Methylphenidate is the drug of choice for
ADHD treatment (Swanson & Volkow, 2002). The
drug shows a high affinity for the DAT and NET
and much less tbr the serotonin transporter (SERT)
(Gatley et al., 1996). The in vivo potency of
methylphenidate on the DAT in the human brain is
similar to that of cocaine (Volkow et al., 1999).
Additionally, its psychopharmacological properties,
evaluated in behavioral, assays are similar to those
of cocaine (Gatley et al., 1999). The therapeutic
mechanism of action of methylphenidate in ADHD
is very complex and is related to chronic treatment82 E. CARBONI AND A. SILVAGNI
with oral doses. Methylphenidate, given orally to
humans, blocks up to 60% of DAT sites (Volkow
et al., 2002) and increases extracellular dopamine
concentrations in the striatum by 16 + 8%. If we
assume that DAT function is higher in ADHD
patients than in unaffected subjects, then this
effect could compensate the reduced dopamine
function resulting from DAT overexpression.
Moreover, the overexpression of DAT sites could
be the primary alteration in the dopamine
transmission machinery. This alteration, in the
absence of an augmented firing, would therefore
generate a reduction in the synaptic dopamine
concentration, determining a reduced dopamine
function. This possibility would be in agreement
with the ’dopamine hypofunction hypothesis’
(Sagvolden & Sergeant, 1998). This hypothesis is
mainly based on the mechanism of action of
methylphenidate, a first drug of choice in ADHD
therapy, and is supported by the higher number of
DAT sites found in SHR rats as compared with
WKY (Watanabe et al., 1997) but not by the gene-
expression studies that have shown a lower level
ofDAT in SHR as compared with WKY rats (Leo
et al., 2003).
On the other hand, methylphenidate, at oral
doses in the range of those that are used in ADHD,
reportedly increases norepinephrine in the hippo-
campus and in the PFCX, but not in subcortical
striatal areas (Kuczenski & Segal, 2002). This
effect might be the result of a methylphenidate-
induced blockade of the NET (Gatley et al., 1996).
This effect, in turn, might be shared by anti-
depressants that are currently used clinically
(Pliszka, 2003). Tricyclic antidepressants have
indeed an efficacy comparable to that of
stimulants, although several side effects may
hamper their use (Spencer et al., 2002). In
particular, the specific NET blocker atomoxetine
increases the concentration of norepinephrine and
dopamine in the PFCX, without affecting
serotonin, whereas it does not change dopamine
concentration in the striatum (Bymaster et al.,
2002). Atomoxetine is well tolerated and has been
proposed as a valuable new treatment option for
adults with ADHD (Simpson & Plosker, 2004). In
agreement with a major role of norepinephrine in
the amphetamine therapeutic effect is the obser-
vation that amphetamine releases norepinephrine
more potently than dopamine and serotonin do,
and that the oral dose of these stimulants, which
produce amphetamine-type subjective effects in
humans, correlates with the their potency .n
releasing norepinephrine but not ciopamine (Rotman
et al., 2001).
Elevated dopamine transmission, on the other
hand, has been considered a possible cause of the
ADHD disorder (Papa et al., 2002; Seeman &
Madras, 2002). According to this hypothesis,
methylphenidate, by increasing the dopamine
concentration on the D2/D3 autoreceptor, would
reduce tonic dopamine release and postsynaptic
dopamine function (Grace 1991,2001).
Synaptosomes and vesicle studies
Synaptosomes are synpatic terminals in
suspension, obtained by a process that includes
gently grinding brain tissue in an isotonic solution
and various centrifugations (Whittaker et al.,
1964). Synaptosomes can be used not only to study
uptake and neurotransmitter release but also to
prepare neurotransmitter vesicles upon osmotic
shock. The evaluation of dopamine release in
synaptosomes relies on the estimation of the tracer
3H-dopamine released together with endogenous
dopamine by an artificial depolarization, usually
obtained by altering the concentration of K
/ and
Na
/ in the medium or by changing the electrical
field stimulation (Middlemiss & Hutson, 1990;
Sandoval et al., 2001; Bowyer et al., 1987).
Because 3H-dopamine must be previously
loaded in the synaptosomal vesicles to be released,
the study of dopamine release from synaptosomes
relies on the assumption that the dopamine
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loaded with newly synthesized dopamine in the
terminal. This assumption is sustained by the
observation of Cerrito et al. (1980), who reported
that newly synthesized and recaptured dopamine
have similar compartmentation in nerve endings.
Alternatively, the endogenous transmitter released
from synaptosomes can be assayed by HPLC
(Middlemiss & Hutson, 1990).
The effect of amphetamine on neurotransmitter
release in synaptosomes and vesicles has been
studied widely. Amphetamine can enter into the
synaptosomal preparation through a saturable active
transport, as studied by the uptake of 3H-amphet-
amine (Zaczek et al., 1991). Amphetamine can
determine the release of previously loaded 3H-dop-
amine from striatal synaptosomes vesicles that share
the feature of being the target of reserpine
(Masuoka, 1982). As mentioned in the previous
paragraph, besides dopamine, amphetamine and
related psychostimulants like 3,4-methylenedioxy-
methamphetamine (MDMA), (+)-methamphetamine,
and ephedrine release norepinephrine more potently
than they release dopamine and serotonin (Rothman
et al., 2001). Furthermore, the authors showed that
whereas the psychostimulants rank order of potency
for dopamine release was similar to their rank order
of potency in published self-administration studies;
the oral dose of these stimulants, which produce
amphetamine-type subjective effects in humans,
correlate with their potency in releasing nor-
epinephrine not dopamine. This observation can
influence future research on the mechanism of
action of amphetamine in relation to the therapeutic
effect on ADHD.
An interesting effect of amphetamine, which
might also have implications in ADHD therapy, is
its action on dopamine synthesis. The stimulation of
dopamine synthesis in rat brain striatal synapto-
somes produced by the depolarizing agent
veratridine is markedly reduced by prior in vivo
amphetamine administration (Patrick et al., 1981).
On the other hand, it has been suggested that
amphetamine can increase dopamine synthesis,
apparently through a mechanism that depends on a
functioning uptake carrier as it is prevented by
uptake inhibitors like nomifensine and benztropin
(Connor& Kuczenski, 1986).
Amphetamine increases particulate protein
kinase C (PKC) activity in striatal synaptoneuro-
somes. The increased PKC activity is linked to the
outward transport of dopamine and when the
release is diminished, the inward transport of
amphetamine inhibits PKC instead (Giambalvo,
2003). It would be interesting to test this evidence
in synaptoneurosomes from SHR and WKY rats to
ascertain any differences that could be related to
the different sensitivity of dopamine release due to
amphetamine in vivo and in slices (Russell et al.,
1998; Carboni et al. 2003).
Among other effects of amphetamine that have
been shown in synaptosomal preparations and might
have implications in its therapeutic effect is the
ability of amphetamine to alter phosphorylation-
related second messenger activities. In particular,
amphetamine can enhance the phosphorylation of
the neural-specific calmodulin-binding protein,
neuromodulin, which, in turn, could contribute to
neurochemical events leading to the enhanced
release of dopamine and/or a behavioral sensitiza-
tion (Gnegy et al., 1993). Amphetamine can also
increase the phosphorylation of synapsin in rat
striatal synaptosomes, which in turn can play a
role in enhanced dopamine release (Iwata et al.,
1997). A last interesting observation was obtained
in synpatosomes from SHR rats and from WKHA
rats, a strain characterized by developing hyper-
activity but not hypertension. In SHR rats, a
significant increase in norepinephrine uptake,
primarily through an increase in Vmax in cerebral
cortical areas and the cerebellum, is associated
with the hypertensive trait, whereas a significant
increase in dopamine uptake Vmax in the frontal
cortex is associated with the inheritance of hyper-
activity among these strains (Hendley& Fan, 1992).84 E. CARBONI AND A. SILVAGNI
Slice studies
Another method that has been used to study
dopamine release and the effects of drugs used in
ADHD therapy is based on the use of slices
obtained from a specific brain area. Slices can be a
valuable tool for investigating physiological and
pharmacological process occurring at the neuron
terminal level because drugs can be applied in a
relatively quantitative manner, and the effect on
the release of a neurotransmitter can be cleaner
than the one observed with in vivo methods.
(Dunwiddie & Basile 1983). In slices, dopamine
release can be evaluated either by assaying endo-
genous dopamine or by preloading storage vesicles
with 3H-dopamine. In the latter case, the amount of
radioactivity released into the perfusion chamber,
after either an electrically or chemically triggered
depolarization, obtained by changing K+/Na+
concentration in the medium, allows the evaluation
of the effect of drugs on depolarization-dependent
dopamine release (Dunwiddie & Basile 1983;
Russell 2000; Schmitz et al., 2003).
An interesting study that might have
implications for ADHD therapy was performed in
striatal slices (Gifford., 2000). Here the author
showed that amphetamine-evoked dopamine release
at a concentration of 30 micromolar reduced 3H-
raclopride binding by 77% with a 50% inhibition at
a a concentration of 1.6 micromolar. Amphetamine-
evoked dopamine release did not have a significant
effect on 3H-SCH 23390 binding, suggesting that
dopamine release evoked by low doses of
amphetamine would probably act on D2 rather
than on D receptors. This view could apply to the
striatum only because an interesting role of D1
transmission in the PFCX related to attentional
performance has been suggested recently (Granon
et al., 2000).
Moreover, in a striatal slice preparation, Park
and Park (2000) showed that 74% of 3H-raclopride
binding was displaced by the dopamine released
by amphetamine, and that synaptic dopamine
concentration should correspond to 1.6 nM. The
development of electrochemical recording with
small carbon-fibers electrodes has permitted the
advancement of the knowledge on catecholamine
transmission and its presynaptic regulation (Schmitz
et al., 2003).
A study using fast cyclic voltammetry reported
that the synaptic dopamine concentration evoked
by micromolar amphetamine was about 0.6 and
0.27 micromolar in the caudate putamen and the
NAc, respectively (Wieczorek & Kruk, 1994). The
action of amphetamine was also investigated using
fast-scan cyclic voltammetry by Jones et al.
(1998). The authors confirmed not only that DAT
is essential for amphetamine-induced dopamine
release but also that amphetamine can pass
through the plasma membrane to deplete terminal
vesicles, as demonstrated by the disappearance of
electrically stimulated dopamine release in striatal
slices ofDAT-KO mice after the application of 10
micromolar amphetamine. The authors also reported
that amphetamine vesicle depletion prevents
dopamine electrically stimulated release, probably
by affecting all the dopamine containing vesicle in
wild type mice. This observation is apparently in
contrast to the observation of Anderson et al.
(1998), who reported that only large dense-core
vesicles (LDCV) are affected by low doses of
amphetamine because it has to be considered that
the results were obtained in two different models,
a mammal on one side and a mollusk (Planorbis
corneus) on the other. The evaluation of the
synaptic dopamine concentration evoked by
amphetamine can therefore provide useful insight
into the indirect receptor activity of amphetamine,
although the dopamine concentration measured
differs from study to study.
The response of slices obtained from brain
areas involved in ADHD, such as the caudate
putamen, NAc, and PFCX, to methylphenidate and
amphetamine has been widely investigated by
Russell and coworkers (Russell et al., 1995, 1998;
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NAc slices of SHR rats, methylphenidate (10
micromolar) released dopamine to a lesser extent
than in WKY rats. By contrast, amphetamine
stimulated dopamine release to a greater extent in
NAc slices from SHR rats than in those from
WKY rats. These effects, however, were obtained
only at one of the drug concentrations tested.
Electrical depolarization, in the presence or in the
absence of methylphenidate, on the other hand,
stimulated the release of 3H-dopamine in the NAc
of SHR to a similar extent as in the NAc ofWKY
rats. On the other hand, the depolarization (25 mM
K/)-induced release of dopamine from NAc slices
of SHR rats was significantly lower than in those
from WKY rats (Russell, 2000).
The possibility that amphetamine interacts
with dopamine release triggered by high potassium
was investigated in striatal synaptosomes and
slices by Bowyer et al., (1987). The authors
reported that amphetamine evokes 3H-dopamine
release and inhibits the subsequent K/-evoked 3H-
dopamine release at a flow perfusion that prevents
reuptake, whereas at a flow rate that allows the
reuptake, the effect of amphetamine is of lesser
extent. On the basis of these results, Bowyer et al.
suggested that amphetamine can open voltage-
dependent Ca
+/ channels that are sensitive to
cobalt but not to nifedipine, and that amphetamine
can desensitize these voltage-dependent Ca
+/
channels and inhibit their activation by K
/
depolarization. This observation parallels the
amphetamine effect of preventing the electrical
stimulation of dopamine release in striatal slices
(Jones et al., 1998).
Whole cell studies
Some interesting insight into the mechanism of
action of amphetamine was recently provided by
Khoshbouei et al. (2003). The authors, using the
patch clamp technique in the whole-cell configuration
combined with amperometry on human embryonic
kidney HEK-293 cells stably transfected with the
human DAT, observed that the dopamine efflux
mediated by DAT is voltage dependent, electro-
genie, and dependent on the intracellular Na
/
concentration in the recording electrode. On this
basis, the authors suggested that the transport of
amphetamine ater binding to the DAT causes an
inward current, which in turn increases the intra-
cellular concentration of Na/, thereby enhancing
the DAT-mediated reverse transport of dopamine
toward the synaptic space.
Studies on cells have also suggested a different
action of amphetamine on terminal vesicles.
Indeed, it has been reported that using carbon fiber
microelectrodes, currents transients corresponding
to individual exocytotic events can be recorded
from the cell body of the dopamine-containing
neuron of the giant dopamine cell of Planorbis
corneus (Anderson et al., 1998). In these
preparations, amphetamine at low doses selectively
caused the depletion of LDCV, leaving intact the
small synaptic vesicles (SSV), although SSV
vesicles should be located densely packed in the
plasma membrane vicinity. At high doses,
amphetamine depletes small vesicles more strongly
than large vesicles but continues to deplete large
vesicles in a dose dependent manner. On the other
hand, in rat NAc catecholamine terminals, identified
by immunocytochemical localization of TH, both
LDCV and SSV were detected (Bouyer et al.,
1984). The authors also reported that a certain
proportion of TH-containing terminals within the
NAc are morphologically distinct from the
catecholaminergic terminals within the dorsal
striatum.
If we now assume that in the rat neuron,
specifically in NAc terminals, some of the above
described mechanisms occur, then it becomes
challenging to speculate that the higher amount of
dopamine released by amphetamine in SHR rats
than in WKY rats (Carboni et al., 2003) could be
due to the capability of low doses of amphetamine
to deplete a pool ofLDCVs that might be located in
greater proportion in SHR terminals. On the other86 E. CARBONI AND A. SILVAGNI
hand, the larger dopamine release observed in WKY
rats resulting from depolarization by high K
+ might
be explained, supposing that high K
+ acts at least
preferentially on the SSV-containing dopamine
pool, which is larger in WKY rats than in SHR rats.
Therefore, it cannot be excluded that a different
distribution ofLDCV and SSV in the catecholamine
terminals of basal ganglia and eventually in other
brain areas, might be a morphological and functional
feature that plays a role in the etiology ofADHD.
In vivo studies
Among the methods used to elucidate the
mechanisms involved in the release of a neuro-
transmitter, microdialysis offers the advantage of
evaluating the concentration of a transmitter in the
dialysate, which directly reflects the extracellular
concentration at the synaptic clefts. The concentra-
tion at the synaptic clefts, in turn, depends on the
amount released by a firing- and calcium-dependent
process and on the efficiency ofthe reuptake system
in removing the transmitter from the synaptic cleft.
Dopamine release from both dendrites and
terminals can be assayed in vivo in unanesthetized
rats using the microdialysis method (Di Chiara,
1990; Di Chiara et al., 1996; Justice, 1993; West-
erink, 2000; Carboni, 2003). The microdialysis
technique, therefore, allows the evaluation of
endogenous dopamine that, after being released by
a depolarization/ calcium-dependent process,
escapes from the synaptic clet, and reaches the
microdialysis fiber to be collected in the artificial
cerebrospinal fluid. Moreover, the synaptic
dopamine concentration is dependent on the
capturing capability of the DAT and therefore
depends on the firing activity of the terminal and
on the density of DAT sites in the area studied.
Even in microdialysis, it is possible to study
dopamine release triggered by an artificial
depolarization, which can be achieved in the area
surrounding the microdialysis fiber by perfusing
the fiber with an artificial cerebrospinal fluid
containing an elevated K
+ concentration.
The acute and chronic effects of amphetamine
and/or methylphenidate have been widely studied
by microdialysis (Carboni et al., 1989; Cadoni et
al., 1995; Kuczenski et al., 1995; Carboni et al.,
2003). Cadoni et al. (1995), investigating the role
of vesicular and newly synthesized dopamine in
the action of amphetamine, reported that the
increase of extracellular dopamine evoked by
amphetamine (0.2 and 0.5 mg/kg s.c.) in the dorsal
striatum, was only parti’ally prevented by the
blockade of dopamine synthesis by alpha-methyl-
p-tyrosine pretreatment or by the inactivation of
vesicular amine uptake by reserpine pretreatment.
The combined treatment instead produced a
dramatic reduction of the amphetamine-evoked
dopamine output.
Kuczenski et al. (1995) reported that both
amphetamine and methylphenidate (2 mg/kg s.c.)
promote the equivalent increase of dopamine
output in the caudate, whereas amphetamine is
more potent in raising the synaptic concentration of
norepinephrine in the hippocampus. We recently
reported (Carboni et al., 2003) that the systemic
administration of amphetamine (0.25 and 0.5
mg/kg s.c.) and methylphenidate (1 or 2 mg/kg
i.p.) produces a higher increase in dialysate
dopamine in the shell of SHR than in the shell of
WKY rats. In contrast, when the microdialysis
fiber was perfused with 30 or 60 mM K
+ through
reverse dialysis, the increase of the dialysate
dopamine was lower in SHR rats than in WKY
rats. The results, compared and critically discussed
with the results of other studies investigating the
effect of amphetamine, methyl-phenidate, and high
potassium depolarization, using in vitro
preparations, suggest the existence of different
dopamine-containing vesicle pools in the NAc
shell dopamine terminals ofSHR and WKY rats.
Moreover, we reported that the basal extra-
cellular dopamine concentration in the NAc shell
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other hand, no difference between SHR and WKY
rats, in both basal and amphetamine-induced
striatal dopamine release and metabolites, was
found by Ferguson et al. (2003). This result is in
contrast with what we recently reported (Carboni
et al., 2003), but an explanation can be found in
the different age of the rats used (6-week-old rats
in our study versus 19-week-old rats in the
Ferguson study) and in the brain area investigated
(NAc in our study, striatum in Ferguson study).
Yu et al. (1990) found no difference between
dopamine levels in the striata and NAc from 9-
week-old WKY and SHR rats. In groups treated
acutely with cocaine, the dopamine levels in these
two brain regions were surprisingly unaffected,
whereas 2 h after the administration of cocaine,
both strains showed a significant increase in
striatal HVA. Subacute cocaine administration in
WKY and SHR, however, affected dopamine
levels in the striata and NAc differently. One more
study reported a positive, linear correlation
between the extracellular levels of dopamine and
cocaine for the 60-min period following acute
cocaine administration in both SHR and WKY
rats. On the other hand, the slope of the linear
regression plots obtained from the data of each 15-
min sample was slightly, but significantly, higher
in conscious SHR than in conscious WKY (Inada
et al., 1992).
In summary, in vivo microdialysis studies have
been revealed as a very useful tool for investigating
the effect of amphetamine and methylphenidate in
either normotensive or hypertensive rats, although
the differences in the brain area investigated and in
the age of the rats hamper a direct comparison of
the results.
DISCUSSION
Synaptic release and consequently the extra-
cellular concentration of dopamine measured
depend on a sequence of events that begins with
terminal depolarization and ends with the reuptake
or the diffusion the transmitter. The higher extra-
cellular concentration of dopamine observed in the
NAc of SHR rats than in the NAc of WKY rats
(Carboni et al., 2003) suggests that in SHR rats,
synaptic transmission in the NAc occurs by means
of a higher dopamine concentration in the synaptic
clett. The elevated synaptic dopamine concentration
cannot be recognized as being due to either
elevated tonic or elevated phasic activity because
phasic activity can be measured on a subseconds to
seconds timescale (Venton et al., 2003; Grace,
1991, 1995), whereas the amount of transmitter
assayed by the microdialysis technique represents
an estimate of the average dopamine concentration
present at the synaptic clet for the collecting time
(20 min). Therefore, the higher synaptic dopamine
concentration observed in the NAc of SHR rats
can be attributed to a dysfunction at different
levels, such as dopamine synthesis, dopamine
storage, dopamine metabolism, dopamine reuptake,
autoreceptor function, postsynaptic receptor
activity, and transduction mechanisms.
Unfortunately, basal release cannot be estimated in
synaptosomes and might be hampered in slices
because of an interruption in the cell body-
terminal connections; therefore, no comparison
with the results obtained in vitro can be made.
Although the differences observed in NAc-
basal dopamine release is of limited entity, this
dissimilarity could represent a crucial transmission
alteration that might be involved in the expression
of the typical behavioral observed in SHR rats
(Knardahl & Sagvolden, 1979), and it is possible
to speculate that children affected by ADHD might
have in common with SHR rats an elevated
dopamine transmission in the NAc. This view is
supported by the increase in TH activity found in
another animal model of ADHD, the Naples high-
excitability (NHE) rat (Viggiano et al., 2000,
2002). If one assumes that the SHR phenotype is a
model of ADHD, then the higher dopamine basal
concentration found in the NAc of SHR as88 E. CARBONI AND A. SILVAGNI
compared with WKY rats (Carboni et al.,2 003)
favors a hyperdopaminergic hypothesis of this
condition. Moreover, SHR rats showed a more
pronounced increase of extracellular dopamine in
the same area after challenge with amphetamine
and methylphenidate. The clear-cut difference
between SHR and WKY rats in the responsiveness
of NAc-shell dopamine to methylphenidate is
particularly relevant, given that this drug is to date
the treatment of choice for ADHD. An increased
dopamine synthesis in SHR rats seems also
supported by the higher expression of TH mRNA
levels (Kumai et al., 1996) and TH gene
expression (Reja et al., 2002) in the medulla
oblongata of SHR rats. On this basis, it has been
speculated that an increased dopamine output in
the NAc would be compensating for a reduced
transduction mechanism (Papa et al., 1998).
Consistent with this proposal might be the reduced
number of CaMKII-positive elements identified in
the anterior portion of the shell together with a
lower expression of c-FOS.
The larger increase of dialysate dopamine
caused by a low doses of amphetamine in SHR, as
compared with WKY rats (Carboni et al., 2003), is
difficult to attribute to a specific mechanism,
considering the existence of multiple evidence and
a hypothesis on the mechanism of action of
amphetamine. Although many differences are due
to the methodology used, the comparison of our
data with those from a few in vitro studies in slices
conducted by Russell et al. (1998) allows us to
point out some common evidence. The authors
indeed showed that in slices obtained from the
accumbens of SHR and WKY rats, the effect of
amphetamine on dopamine release, at the lower
dose tested, was higher in SHR than in WKY rats.
Moreover, amphetamine at higher doses produced
a bigger increase in dopamine release in PFCX
slices from SHR than in those from WKY rats.
The data are in agreement with a recent
observation in our laboratory. We indeed found
that amphetamine releases more dopamine in the
PFCX of SHR rats than in WKY rats (Carboni et
al., unpublished observations).
When dopamine release is evoked by high K
/
concentrations, SHR and WKY rats respond in a
strikingly different manner (Carboni et al., 2003).
Therefore, if amphetamine releases more dopamine
from the NAc shell ofSHR rats than from the shell
of WKY rats, then the depolarization obtained by
perfusion with high-K
+ Ringer’s solution releases
more dopamine in WKY than in SHR rats. The
data suggest that (a)two pools of releasable
dopamine might be available in accumbal dopamine
terminals; (b) the pools are differently affected by
amphetamine and high K/, and (c) they represent a
different source of releasable dopamine in the rat
strains SHR and WKY. Our result is in agreement
with that reported by Russell (2000). The authors
reported indeed that the 25 mM K/-evoked
dopamine release in NAc slices from SHR rats is
much lower than that observed in slices from
WKY rats. It is interesting to note that such a
difference was not observed when depolarization
was triggered by electrical stimulation (Russell et al.,
1998). A higher effect of high K
/ in SHR rats was
reported recently (Yousfi-Alaoui et al., 2001). The
authors showed that 15 mM K/-evoked
3H-dopamine overflow is lower in the striatum and
PFCX synaptosomes from SHR as compared with
WKY rats. This evidence allows us to suggest that
3H-dopamine used as a tracer in both synaptosomes
and slice preparations is evenly distributed among
vesicles, no matter if two pools of vesicles
eventually are differently mobilized by high K
/ or
by amphetamine.
We recently reported that methylphenidate
enhances the extracellular dopamine concentration
in the NAc of SHR more than in WKY rats
(Carboni et al., 2003). The data from that study,
when compared with the data obtained by Russell
et al. (1998), are different regarding the effect of
methylphenidate. Indeed Russell et al. reported
that the methylphenidate effect on the electrically
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in slices obtained from the NAc ofWKY or SHR
rats. At the moment, we do not have an explanation
for such diversity, but the different density and
location ofDAT sites in areas such as the NAc, the
caudate, and the PFCX may be relevant. The DAT
indeed can be densely packed in the synaptic cleft
vicinity but also more sparsely located far from the
synaptic cleft (Sesak et al., 1998), and this feature
might affect the results obtained by different
methods. If indeed the dialysate concentration of
dopamine measured through the microdialysis
technique depends strongly on the DAT function
in the striatum, and in the cortex it has been
considered that dopamine can be captured also by
the NET (Carboni et al., 1989, 2001), therefore the
evaluation of dopamine release and the influence
ofDAT in slices, and even more in synaptosomes,
may be different because dopamine is released in
much larger spaces.
Upon studies on slices, Russell et al. (2000)
concluded that in SHR rats, the DAT function is
not probably different from that in WKY rats. If
we assume that this conclusion is correct, our data
would suggest that the higher effect of methyl-
phenidate observed in SHR rats as compared with
WKY rats is merely due to a higher release of
dopamine in the synaptic cleft, which is, in turn, in
agreement with the higher dopamine basal
concentration found in the NAc of SHR rats as
compared with WKY rats. This point of view
would therefore strengthen the hypothesis (Russell,
2000) that the difference between SHR and WKY
rats regarding the response to amphetamine and to
high K
/ lies at the vesicle level.
A further mechanism in which amphetamine is
involved is the so called ’redistribution’ ofVMAT-2
in dopamine terminals (Sandoval et al., 2001,
2002; Fleckenstein & Hanson, 2003). A single
dose of amphetamine indeed, causes a reversible
decrease in the function of dopamine uptake in a
purified vesicle-enriched fraction and a consequent
rise in the extracellular dopamine concentration,
with ..more chances that reactive species derived
from oxygen degradation products are formed in
the dopamine terminal. An opposite effect has
been reported for methylphenidate that instead, it
increases dopamine uptake in the vesicle-enriched
fraction whilst increasing the number of VMAT-2
sites in the same fraction and decreasing them in
plasmalemma-enriched fractions (Fleckenstein &
Hanson, 2003). It is hard to position VMAT-2
’redistribution’ in the mechanism of action of
psychostimulants in ADHD therapy because both
amphetamine and methylphenidate have been used
alternatively with therapeutic benefit, but
considering the localization of VMAT2 in VTA
neurons (Nirenberg et al., 1996) and the effect of
amphetamine in KA1 VMAT2 mutant mice ( Patel
et al., 2003), it cannot be excluded that the defect
present in SHR rats and eventually in ADHD is at
the level of different LDCV and SSV density
and/or VMAT2 expression in the vesicles.
In conclusion, this study supports the usefulness
of investigating dopamine release in SHR and
WKY rats using different methods for improving
either the knowledge on vesicle trafficking at the
dopamine-terminal level or the knowledge of the
mechanism of action of amphetamine and
methylphenidate, therefore contributing to the
understanding ofADHD etiology.
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